Research programme: small molecule therapeutics - Rafael Pharmaceuticals

Drug Profile

Research programme: small molecule therapeutics - Rafael Pharmaceuticals

Alternative Names: CPI 1826; CPI 3220; CPI 618; CPI-3514; CPI-3517

Latest Information Update: 12 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cornerstone Pharmaceuticals
  • Developer Rafael Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Haematological disorders

Most Recent Events

  • 12 Jun 2017 Preclinical development is ongoing for Cancer in USA (Rafael Pharmaceuticals pipeline, June 2017)
  • 12 Jun 2017 Preclinical trials in Haematological disorders in USA (PO) before June 2017 (Rafael Pharmaceuticals pipeline, June 2017)
  • 05 Jun 2017 Cornerstone Pharmaceuticals is now called Rafael Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top